



# Proactive Oncology Care at Scale

Turning Patient-Reported Outcomes into Action

# Our Speakers



**Nadia Still**

VP, Client Success



**Kristen Dininno**

Lead, Client Success



**Christina Sigler**

Clinical Practice  
Transformation  
Advisor



**Debra Wujcik**

Director, Research  
Consultant

# Agenda

- Customer Testimonials
- Clinical Applications
- Our ePRO Collection
- Research Applications
- Q&A

Our mission is to be the catalyst for  
*massive, measurable, data-informed*  
healthcare improvement.



# The Carevive™ Difference

We are the connective tissue in oncology care, a platform that **turns the patient experience into clinical action**, and **real-world data into evidence** that moves the entire ecosystem forward.

***We've been on the journey with you for 15 years***


*Others offer point solutions or force you to adapt to their technology.*

*Carevive by Health Catalyst® brings deep oncology healthcare expertise, comprehensive capabilities across cost, quality, and consumer experience, and a track record of delivering measurable results when it matters most.*



# Cancer Care Has Left the Building

How patient-reported outcomes can change proactive cancer care at scale



# Audience Poll 1

How would you describe your organization's use of patient reported outcomes?

**A**

Not using PROs, but exploring/planning to implement

**B**

Collecting PROs for limited use (pilots, specific clinics, or research)

**C**

Routinely collecting PROs, but not consistently integrated into clinical workflows

**D**


Fully integrated PROs into clinical care (e.g., alerts, longitudinal tracking)

# Customer Testimonials

Kristen Dininno


# Customer Testimonials

## *PROs and Alerts*



### **Comprehensive ePRO Capture**

40+ validated oncology PRO instruments  
Tracks symptoms, function, distress, and treatment adherence  
Continuous patient input across the care journey



### **Smart, Real-Time Alerting**

Risk-based thresholds trigger alerts automatically  
Instant notifications for worsening symptoms or concerns  
Trend tracking identifies issues early



### **Enabling Proactive Care**

Supports timely clinical intervention  
Improves symptom management and patient engagement  
Drives more personalized, data-informed decisions

## USE CASE #1

### Avoiding Unplanned Care & Costs

#### Large Academic Cancer Center (AL)

- Medical Oncology provider and team deliver treatment care plans to all patients and uses RSM to manage ongoing symptom burden of pts while on active treatment
- *Patient reported feeling fine in clinic; RSM detected a UTI early, enabling treatment and avoiding an ED visit*

Featured in an ASCO Poster Presentation

## USE CASE #2

### Improved Operational Efficiency

#### Growing Community Cancer Center (WV)

- Nursing Navigation team tracks oral oncolytic adherence without manual outreach or spreadsheets
- Nursing Clinical Lead: “ePROs and alerts allow our team to proactively manage barriers and improve patient medication adherence”

**AONN 2025 Annual Awards** Exceptional Research in Navigation Award in Category VI: *Research, Quality, Performance Improvement*

## USE CASE #3

### Scaling Multidisciplinary Care

#### Community Cancer Center (NJ)

- Radiation Oncology team screens distress at scale with automated follow-up, eliminating paper workflows
- Provides a daily worklist for social work team

# Audience Poll 2

What is your organization/company's biggest barrier to acting on PROs?

**A**

Not currently using PROs, but exploring or planning implementation

**B**

Collecting PROs in limited settings (e.g., pilots, specific clinics, or research), but lacking resources or confidence to scale

**C**

Routinely collecting PROs, but limited by staff time, workflow integration, or clarity on how to act on results

**D**

PROs are integrated into clinical workflows, but opportunities remain to optimize consistent action and care team engagement

# Clinical Applications

Christina Sigler

# ePROs in Cancer Care help to ...



Center the patient and their values and priorities



Facilitate proactive symptom management, deliver timely interventions, and promote interdisciplinary collaboration



Collect independent prognostic information for cancer survival



Streamline and ensure consistency of data collection



# Carevive's Unified Dashboard

## Centralized Cancer Insights

Integrates clinical, treatment, and patient-reported data into one streamlined view for a holistic understanding of patient progress.

## Real-Time Monitoring

Tracks symptoms and treatment adherence, enabling early intervention and personalized care.

## Data-Driven Decisions


Visual analytics highlight care gaps and trends to inform proactive clinical action.

## Teamwide Coordination

Serves as a shared source of truth to align care teams and improve communication.

## Value-Based Care Support

Drives better outcomes, satisfaction, and efficiency—critical for value-based models.












# Our ePRO Collection

What We Can Measure & Why

# A Comprehensive Survey Library

Examples of Validated Tools Utilized to Drive Oncology Care Excellence:

Foundational & Screening	
	Core Assessment (Baseline)
	NCCN Distress <i>Thermometer</i>
	PHQ-2 / PHQ-9 ( <i>Depression Screening</i> )
Treatment & Monitoring	
	Treatment Planning Assessment
	Remote Symptom Management
	Oral Therapy Adherence
Specialty & Supportive Care	
	IEC Therapy Assessment
	Pancreatic Supplement Assessment
	Palliative Care Assessment

# Baseline ePROs

## Patient Profile & Social Determinants

General information and demographics / socioeconomic factors

## Quality of Life & Global Health

Health-Related QoL - EORTC-QLQ-C30 & PROMIS

## Functional Status & Frailty

FACT, PROMIS & Frailty Index

## Symptom Burden & Severity

PRO-CTCAE, BPI

## Care Experience & Decision Making


Shared Decision-Making, Patient Preferences, Practical & Emotional Concerns

## Healthy Literacy


Understanding of cancer-related information & treatment


## Social Support

Availability of caregiver & community support



# Clinician Dashboard Display

✓  **EMOTIONAL AND PRACTICAL**

 **PATIENT CONCERNS** Last updated: 09/15/2025

1. Am I making the right treatment decision
2. Do I understand my treatment options

✓ **FUNCTIONAL ASSESSMENT OF CANCER THERAPY (FACT)** Last updated: 03/18/2025


**Physical Well Being**


I am bothered by side effects of treatment  **Quite a bit**

✓ **HEALTH-RELATED QUALITY OF LIFE (EORTC-QLQ-C30)** Last updated: 03/18/2025


**Overall Health** 3/18/2025 

**Quality of Life** 3/18/2025 


✓  **GOALS AND DECISION MAKING**

✓  **GOALS OF CARE** Last updated: 08/29/2025

Quality vs. Length of Life	Quality of Life is more important but Length of Life matters
Importance of Quality of Life	Very important
Importance of Length of Life	Moderately important

✓  **SHARED DECISION MAKING STYLE** Last updated: 08/29/2025


With my doctor	Have my doctor and I share responsibility for deciding what treatment is best
----------------	---

✓  **CLINICAL TRIALS** Last updated: 08/29/2025


Interested in Clinical Trials Yes

✓ **FRAILITY INDEX** Last updated: 01/17/2025

**Intermediate Fit**

Frail  Fit

A Frailty Index (FI) Status of *intermediate fit* is determined by a composite score of = 1, from each of the 4 contributing domains (Katz ADL, Lawton IADL, Patient Reported CCI and Age)



Age at time of evaluation: **69** 

# Single-Point & Longitudinal PRO-CTCAEs

SYMPTOM ASSESSMENT USING COMMON TERMINOLOGY CRITERIA, DERIVED FROM THE PRO-CTCAE Last updated: 07/30/2025 NEW

Showing 20 data points More Less

SYMPTOMS	PRESENT	FREQUENCY	SEVERITY	INTERFERENCE
Anxiety	No	Never	None	Not at All
Bruising	No			
Chills	No	Never	None	
Constipation	No		None	
Decreased Appetite	No		None	Not at All
Diarrhea	No	Never		
Fatigue	No		None	Not at All
Fever (100.4 F or higher)	No			
General Pain				
Insomnia	No		None	
Mouth/Throat Sores	No		None	
Muscle Pain	No	Never	None	
Nausea	No	Never	None	
Numbness and Tingling	Yes		Moderate	
Rash	No			
Sadness	No	Never	None	
Shortness of Breath	Yes		Moderate	
Vomiting	No	Never	None	



# Monitoring & Real-Time Alerting

**ALERT**

**Oral Adherence** Open All Expected Level: None

Date	Level	Trigger(s)	Survey	Status	Action(s)	Acknowledged By
02/05/2021	Moderate	Oral Adherence: Sometimes	Core Assessment	Open		

Action(s) Taken:

Internal Notes/Comments Add Notes/Comments

Acknowledgement  
By choosing my user name and s...  
the following action(s) has been t...

**ORAL ADHERENCE** Last updated: 02/03/2021

**Takes medication as recommended** 2/3/2021

Adherence: Fair

Reason for not always taking medication:  
It caused side effects that bothered me

**KNOWLEDGE AND BELIEFS** Last updated: 02/03/2021

Medication Adherence	
I know how to take this medicine as recommended	Agree
I understand why I need to take this medicine	Agree
I believe it is important to take this medicine	Strongly agree
I am supposed to take this medicine	Once per day
I have been taking this medicine	1-2 weeks
I believe this medicine is working	Neither agree nor disagree

**ORAL ADHERENCE** Last updated: 02/03/2021

**Takes medication as recommended** 2/3/2021

Date	Adherence Level
2/3/21	Almost Always
2/3/21	Always
2/3/21	Always
2/3/21	Sometimes
2/3/21	Sometimes
2/3/21	Sometimes
2/3/21	Sometimes
2/3/21	Sometimes

# Elevated Alert Thresholds

## Systemic & Constitutional Symptoms

- Bruising
- Chills
- Decreased Appetite
- Fatigue
- Fever

## Psychological & Sleep Symptoms

- Anxiety
- Depression / Sadness
- Insomnia
- NCCN Distress

## Physical Symptoms (Core)

- Cough
- Shortness of Breath
- Diarrhea
- Urinary Problems
- Mouth/Throat Sores
- Nausea
- Vomiting
- Neuropathy
- Pain (muscle/general)
- Rash

## Treatment Management & Risk Monitoring

- Oral Adherence
- Malnutrition Risk
- Neuro Toxicity (ICANS)
- Financial Distress

# Customized ePRO Workflows

Prevent Alert Fatigue. Enable Earlier Intervention. Improve Outcomes.

Smart, targeted ePROs alerting ensures the **care team** takes action – so **patients get help sooner and outcomes get better**



# Audience Poll 3

Which clinical area would you be most interested in capturing through ePROs?

**A**

Symptom burden and treatment side effects (pain, fatigue, nausea)

**B**

Psychosocial indications (anxiety, depression, distress)

**C**

Disease-specific PROs ( MST, PEI, IEC assessment)

**D**

Functional Status & Quality of Life (mobility, daily activity, sleep, QoL metrics)

# Research Applications

Debra Wujcik, PhD, RN, FAAN

# PRO-CTCAE and CTCAE

Common Terminology Criteria for Adverse Events (CTCAE)					
Adverse Event	Grade				
	1	2	3	4	5
<b>Mucositis oral</b>	Asymptomatic or mild symptoms; intervention not indicated	Moderate pain; not interfering with oral intake; modified diet indicated	Severe pain; interfering with oral intake	Life-threatening consequences; urgent intervention indicated	N/A

## Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®)

Please think back over the past 7 days:

What was the severity of your MOUTH OR THROAT SORES at their WORST?  
None / Mild / Moderate / Severe / Very severe


How much did MOUTH OR THROAT SORES interfere with your usual or daily activities?  
Not at all / A little bit / Somewhat / Quite a bit / Very much

Source: Patient Relat Outcome Meas. 2022 Dec 8;13:249–258. doi: [10.2147/PROM.S256567](https://doi.org/10.2147/PROM.S256567)



# Core PROs in Cancer Clinical Trials

Guidance for Industry | Core Concepts




# How do alerts impact patient care?

## Symptom Prevalence Identification

No. of Symptoms Reported per Patient per Week	
Mean (SD)	2.8 (1.6)
Median (IQR)	2.0 (2.0)
Min-Max	1.0 - 10.0


No. of Alerts Reported per Patient per Week	
n (alerts; patients)	513; 58
Mean (SD)	1.7 (1.2)
Median (IQR)	1.0 (1.0)
Min-Max	1.0 - 9.0

## Automatic Healthcare Notification




# How do alerts impact patient care?

## QI Opportunities



## Quantify Patient Reported Tolerability



# What is the role of PROs.....

## In Clinical Trials


- Measure tolerability
- Dose optimization
- Secondary endpoints

## In FDA New Drug Submissions

- Support efficacy and safety
- External control arms
- Label expansion
- Post-Marketing Requirements

# Key Takeaways

Nadia Still

[Schedule a Meeting  
with our Team](#) 

# Meet Us at ISPOR!

**May 17-20, 2026**  
**Philadelphia, PA**  
**Booth #934**

## Poster Presentations

**Identifying Oncology Patient Subtypes Using ePROs Deployed in  
Clinical Practice: A Patient-Centric Approach to Machine Learning**

Monday, May 18, 2026 | 10:30 AM - 1:30 PM

**Enhancing the Care of Patients with Pancreatic Cancer with  
Navigator Facilitated Electronic Patient Reported Outcomes  
(Co-presented with UCLA)**

Tuesday, May 19, 2026 | 10:30 AM – 1:30 PM

# Questions?

**Nadia Still**, VP, Client Success

**Christina Sigler**, Clinical Practice Transformation Advisor

**Debra Wujcik**, Director, Research Consultant

**Kristen Dininno**, Client Success Lead

*For additional questions:*

*[hcwebinars@healthcatalyst.com](mailto:hcwebinars@healthcatalyst.com)*

